They observed that 71% of patients displayed a significant immune response to PD-L1 in the early stages of MPN, and that CD4+ T cells were responsible for the immune response observed, hereby promoting anti-tumor immunity. The gene discussed is CD274; the disease is myeloproliferative disorder.